TScan Therapeutics, Inc. (TCRX) Form 8-K — Sep 2, 2026
TScan Therapeutics announced a strategic reorganization on September 2, 2026, prioritizing its in vivo solid tumor program and pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital. The restructuring includes an approximately 75% workforce reduction, elimination of the internal manufacturing organization, expected charges of about $4.1 million, and targets $55.0 million in cumulative cost savings through the end of 2027, extending the cash runway into Q4 2027.
Key figures
- Cash Runway
- cash, cash equivalents and marketable securities as of June 30, 2026 expected to fund operations into Q4 2027
- Cohort CRFS
- 79% (11/14) at ~6 months post-HCT
- Cohort CRelapse
- 14% (2/14)
- Compliance Deadline
- February 23, 2027 (180 calendar days)
- Workforce Reduction
- approximately 75% of workforce
- Minimum Bid Price Rule
- $1.00 per share
- Deficiency Notice Date
- 2026-08-27
- Restructuring Charges
- $4.1 million employee-related costs (primarily pay continuation and benefits)
- Solid Tumor Milestones
- preclinical data Q1 2027, first IND Q3 2027, Phase 1 initiation Q4 2027
- Cumulative Cost Savings
- $55.0 million through end of 2027
- Cohort CComplete Donor Chimerism
- 13 of 13 patients currently being tracked
- Alloha2 Patients Enrolled Before Pause
- 7
Price after filing
Close on the filing date to close N calendar days later (from $0.38). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.